China is offering coronavirus vaccines under development to workers at state-owned companies in Beijing as the capital city experiences the nation’s biggest flare-up since Wuhan.
The government had earlier
The expanded voluntary inoculation may offer solace to workers facing growing risk as a potential second wave emerges in Beijing. It also puts to the test CNBG’s experimental shots amid a global race to find a successful vaccine to the deadly pathogen.
There are at least five Chinese vaccine candidates in the human trial stage, competing with products being developed by global pharmaceutical companies such as
The new cluster, which emerged from Beijing’s largest wholesale fruit and vegetable market, has grown to more than 175 infections in a week and spread to at least four other Chinese provinces. While the country’s chief epidemiologist said the peak of the outbreak has passed, cases are expected to continue spreading.
The State-owned Assets Supervision and Administration Commission, which oversees China’s government-run companies, didn’t respond to a Bloomberg query. A spokeswoman at CNBG said the company has no information about this expanded inoculation and declined to comment further.
Besides being potentially protected against the virus, those volunteering will also help generate data on the shots’ efficacy against the novel pathogen that has
It isn’t yet known whether CNBG’s vaccines, which employ a dead strain of the novel coronavirus to elicit an immune response from the body, can prevent the infection.
CNBG said that one of the two experimental shots has been found to be generally safe and able to generate neutralizing antibodies, which could latch onto the virus to prevent it from invading cells. Their ability to prevent infection will only be clear in Phase III trials -- the final hurdle to clear for securing marketing approval -- in which thousands of people take the shot to see how effective it is in an active outbreak environment.
Chinese developers were previously concerned that they could not effectively conduct Phase III trials within the country as cases had seemingly dwindled nationwide. But if the resurgence of infections in Beijing isn’t brought under control, it could prompt researchers to consider the possibility of trials at home.
It’s uncertain how many employees of state-run firms traveling overseas or those in Beijing have taken up the offer, and whether they will be tracked for adverse reactions and their immune response.
(Adds background on vaccines and update on Beijing cases beginning with fourth paragraph.)
To contact the editors responsible for this story:
Bhuma Shrivastava, Jeff Sutherland
© 2020 Bloomberg L.P. All rights reserved. Used with permission.